Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18809763 | STRAIN OF LACTOBACILLUS HELVETICUS CAPABLE OF REMOVING MULTIPLE HEAVY METALS AND APPLICATION THEREOF IN GOAT MILK POWDER | August 2024 | March 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18768336 | DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS | July 2024 | February 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18655708 | FimH Mutant, Compositions Therewith And Use Thereof | May 2024 | June 2025 | Allow | 13 | 0 | 1 | Yes | No |
| 18654243 | COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND A FUNGICIDE | May 2024 | April 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18593739 | Enhanced Microbial Therapeutic Agents | March 2024 | February 2025 | Allow | 11 | 1 | 2 | Yes | No |
| 18590885 | AGROBACTERIUM FOR REDUCING UPTAKE OF HEAVY METALS BY WHEAT AND USE THEREOF | February 2024 | May 2025 | Abandon | 14 | 1 | 1 | No | No |
| 18442348 | METHODS OF IMPROVING DESIRABLE TRAITS IN FOWL | February 2024 | June 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18441408 | PREPARATION OF LIVE VACCINES | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | Yes | No |
| 18440278 | MUTANT PORE | February 2024 | March 2025 | Allow | 13 | 0 | 1 | Yes | No |
| 18412561 | Probiotic Formulations for the Treatment and Alleviation of Metabolic and Oxidative Stress, Inflammation and Neurodegeneration | January 2024 | May 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18393572 | Lactococcus Bacteria and Uses Thereof | December 2023 | January 2025 | Allow | 13 | 0 | 1 | Yes | No |
| 18390652 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | December 2023 | March 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18518137 | SHEWANELLA DECOLORATIONIS PRODUCING TETRODOTOXIN AND APPLICATION THEREOF | November 2023 | August 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18507264 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | November 2023 | February 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18493141 | Factor H Binding Protein Variants and Methods of Use Thereof | October 2023 | December 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18490805 | ANTIBACTERIAL TREATMENT METHOD FOR A PATIENT WITH A SKIN WOUND | October 2023 | August 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18463747 | MICROORGANISMS AND METHODS FOR REDUCING BACTERIAL CONTAMINATION | September 2023 | July 2024 | Allow | 11 | 0 | 1 | Yes | No |
| 18463461 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES | September 2023 | November 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18341018 | FIMH MUTANTS, COMPOSITIONS THEREWITH AND USE THEREOF | June 2023 | January 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18213127 | TRIPLE VACCINE PROTECTS AGAINST BACTERIAL AND FUNGAL PATHOGENS VIA TRAINED IMMUNITY | June 2023 | March 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18336614 | OINTMENT-BASED SKIN WOUND TREATMENT METHOD | June 2023 | October 2023 | Allow | 4 | 0 | 1 | Yes | No |
| 18329701 | MENINGOCOCCUS VACCINES | June 2023 | April 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18201595 | IMMUNOGENIC PEPTIDE AGAINST GROUP A STREPTOCOCCUS | May 2023 | May 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18316594 | Factor H Binding Protein Variants and Methods of Use Thereof | May 2023 | June 2024 | Allow | 13 | 0 | 1 | Yes | No |
| 18142216 | COMPOSITIONS AND METHODS FOR A MULTI-ADJUVANT ONLY APPROACH TO IMMUNOPROPHYLAXIS FOR PREVENTING INFECTIONS | May 2023 | August 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18303512 | Influenza vaccine, composition, and methods of use | April 2023 | June 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18122835 | PROBIOTICS AND PROBIOTIC COMPOSITIONS FOR REGULATING BODY WEIGHT | March 2023 | July 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18109970 | IMMUNOGENIC COMPOSITIONS | February 2023 | June 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18156214 | IMMUNOCHROMATOGRAPHIC KIT AND METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSIS | January 2023 | March 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18154177 | IMMUNOGENIC TREATMENT OF CANCER | January 2023 | September 2024 | Abandon | 20 | 2 | 0 | Yes | No |
| 18069759 | COMPOUNDS AND METHODS FOR BIOFILM DISRUPTION AND PREVENTION | December 2022 | May 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18065497 | NOVEL LACTIC ACID BACTERIA AND USE THEREOF | December 2022 | March 2024 | Allow | 15 | 0 | 1 | Yes | No |
| 18055044 | ARTIFICIAL SECRETION PEPTIDES FOR HETEROLOGOUS PROTEIN PRODUCTION | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 18052455 | CHOLIX-DERIVED CARRIERS FOR ORAL DELIVERY OF HETEROLOGOUS PAYLOAD | November 2022 | November 2024 | Abandon | 25 | 1 | 1 | No | No |
| 18051983 | POSTBIOTIC EXTRACT AND PREPARATION PROCESS AND USE THEREOF | November 2022 | January 2024 | Allow | 14 | 0 | 1 | Yes | No |
| 18051968 | POSTBIOTIC EXTRACT AND PREPARATION PROCESS AND USE THEREOF | November 2022 | January 2024 | Allow | 14 | 0 | 1 | Yes | No |
| 18050091 | COMPOSITION FOR DIAGNOSIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE, USING CHANGE IN SHORT-CHAIN FATTY ACID PRODUCING GUT BACTERIAL COMMUNITY | October 2022 | December 2023 | Allow | 14 | 0 | 1 | Yes | No |
| 17938454 | METHODS OF PRODUCING BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | October 2022 | November 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17931356 | METHODS AND COMPOSITIONS RELATED TO THE NEXT GENERATION VACCINE | September 2022 | February 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 17821354 | Protection from Stress, Anxiety, Neuroinflammation, and Cognitive Dysfunction | August 2022 | December 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17816145 | Chimeric proteins for inducing immunity towards infection with S. aureus | July 2022 | September 2024 | Allow | 25 | 0 | 1 | Yes | No |
| 17814966 | FimH mutant, compositions therewith and use thereof | July 2022 | February 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 17814988 | IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE | July 2022 | October 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17813233 | USE OF LACTIC ACID BACTERIA TO TREAT OR PREVENT GESTATIONAL DIABETES MELLITUS | July 2022 | April 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17862295 | TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE | July 2022 | April 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17730909 | Novel PD-L1 Targeting DNA Vaccine for Cancer Immunotherapy | April 2022 | November 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17721115 | VACCINE TO PROTECT A PIG AGAINST ACTINOBACILLUS PLEUROPNEUMONIAE | April 2022 | October 2023 | Abandon | 18 | 2 | 1 | Yes | No |
| 17714361 | COMPOSITION FOR PREVENTING OR TREATING MENOPAUSE, CONTAINING LACTOBACILLUS INTESTINALIS | April 2022 | February 2024 | Allow | 22 | 2 | 0 | No | No |
| 17707132 | METHOD FOR TREATING A SKIN WOUND HAVING A KLEBSIELLA PNEUMONIAE INFECTION | March 2022 | May 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17705913 | VACCINE AGAINST NECROTIC ENTERITIS IN POULTRY | March 2022 | September 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17764153 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF | March 2022 | April 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17762572 | Functional Microbiological Coating | March 2022 | June 2025 | Allow | 38 | 1 | 2 | Yes | No |
| 17574399 | FOOD COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR INHIBITING SJOGREN'S SYNDROME EACH CONTAINING BIFIDOBACTERIUM PSEUDOCATENULATUM C-RAPO (KCTC13986BP) AND BIFIDOBACTERIUM BIFIDUM ATT (KCTC13474BP) | January 2022 | April 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17573249 | FIMH MUTANTS, COMPOSITIONS THEREWITH AND USE THEREOF | January 2022 | March 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17562055 | BORRELIA IMMUNOASSAYS AND MATERIALS THEREFOR | December 2021 | August 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17554424 | E. COLI FIMH MUTANTS AND USES THEREOF | December 2021 | March 2024 | Allow | 27 | 2 | 2 | Yes | No |
| 17643942 | NOVEL LACTOCOCCUS LACTIS SUBSPECIES LACTIS ISOLATE WFLU-12 AND USE THEREOF | December 2021 | March 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17547639 | IMMUNOMODULATORY LIPOPOLYSACCHARIDE COMPOSITIONS | December 2021 | September 2023 | Allow | 21 | 2 | 1 | Yes | No |
| 17544377 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | December 2021 | February 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17543207 | HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS | December 2021 | May 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17533552 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | November 2021 | August 2023 | Allow | 21 | 2 | 1 | Yes | No |
| 17531314 | IN-VITRO POTENCY ASSAY FOR PROTEIN-BASED MENINGOCOCCAL VACCINES | November 2021 | October 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17529396 | Cathelicidin-expressing lactic acid bacteria | November 2021 | September 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17527002 | NOVEL LACTOBACILLUS PLANTARUM STRAIN ATG-K2, ATG-K6 OR ATG-K8, AND COMPOSITION FOR PREVENTING OR TREATING VAGINITIS COMPRISING SAME | November 2021 | September 2024 | Allow | 34 | 3 | 1 | Yes | No |
| 17511544 | APPLICATION OF A BILE ACID COMPOSITE BACTERIAL AGENT IN THE PREPARATION OF FEED ADDITIVES FOR MUTTON SHEEP | October 2021 | January 2023 | Allow | 14 | 1 | 1 | No | No |
| 17486299 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | September 2021 | September 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17478584 | MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF | September 2021 | October 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17474885 | METHOD FOR IMPROVING WALKING CAPACITY OF ELDERLY SUBJECTS | September 2021 | February 2025 | Allow | 41 | 1 | 1 | No | No |
| 17445781 | TEETH CLEANING ANIMAL CHEW | August 2021 | June 2024 | Abandon | 33 | 1 | 1 | Yes | No |
| 17401492 | BIOENGINEERED LACTOBACILLUS PROBIOTICS AND THE USES THEREOF | August 2021 | October 2024 | Abandon | 38 | 4 | 1 | Yes | No |
| 17428487 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17384889 | MUTANT PORE | July 2021 | November 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17371762 | METHODS, COMPOSITIONS AND KITS FOR TREATING A SUBJECT USING A RECOMBINANT HETEROMULTIMERIC NEUTRALIZING BINDING PROTEIN | July 2021 | May 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17359375 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER USING BACTERIA | June 2021 | April 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17356941 | COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND A FUNGICIDE | June 2021 | February 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17356958 | COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND AN INSECTICIDE | June 2021 | January 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17415020 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING INCONTINENCE, OVERACTIVE BLADDER, OR MENSTRUAL CRAMPING | June 2021 | October 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17347413 | MICROORGANISMS AND METHODS FOR REDUCING BACTERIAL CONTAMINATION | June 2021 | August 2023 | Allow | 26 | 0 | 1 | Yes | No |
| 17345576 | DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS | June 2021 | April 2024 | Allow | 34 | 6 | 1 | Yes | No |
| 17340141 | LACTOBACILLUS ACIDOPHILUS SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASES | June 2021 | October 2024 | Abandon | 41 | 2 | 1 | Yes | Yes |
| 17337367 | Mutant Bordetella Strains and Methods of Use | June 2021 | October 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17331776 | SPECIFIC BACTERIA FOR THEIR USE AS A MEDICAMENT, IN PARTICULAR FOR CONTROLLING EXCESS WEIGHT, OBESITY, CARDIOMETABOLIC DISEASES AND INFLAMMATORY BOWEL DISEASES | May 2021 | June 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17320706 | USE OF TLR4 MODULATOR IN THE TREATMENT OF COCCIDIOSIS | May 2021 | April 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17319006 | RATIONALLY-DESIGNED MUTATIONS TO THE THRA GENE FOR ENHANCED LYSINE PRODUCTION IN E. COLI | May 2021 | June 2023 | Allow | 25 | 0 | 2 | Yes | No |
| 17314563 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | May 2021 | February 2022 | Allow | 9 | 1 | 1 | No | No |
| 17306313 | METHODS OF IMPROVING DESIRABLE TRAITS IN FOWL | May 2021 | February 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17228146 | COMPOSITIONS AND METHODS | April 2021 | March 2024 | Abandon | 35 | 1 | 1 | Yes | No |
| 17226761 | PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USE | April 2021 | September 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17221646 | FACTOR H BINDING PROTEIN VARIANTS AND METHODS OF USE THEREOF | April 2021 | February 2023 | Allow | 22 | 0 | 1 | Yes | No |
| 17221177 | VHH BASED BINDING ANTIBODIES FOR ANTHRAX AND BOTULINUM TOXINS AND METHODS OF MAKING AND USING THEREFOR | April 2021 | April 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17220573 | Method of Treating Autoimmune Inflammatory Crohn's Disease | April 2021 | December 2022 | Allow | 20 | 0 | 0 | Yes | No |
| 17301319 | CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY | March 2021 | May 2024 | Abandon | 38 | 5 | 0 | Yes | No |
| 17301331 | CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY | March 2021 | March 2024 | Allow | 35 | 5 | 0 | Yes | No |
| 17203920 | HIGH THROUGHPUT AFFINITY SAMPLE PREPARATION FOR MYCOTOXIN ANALYSIS | March 2021 | July 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17193348 | PIRIN POLYPEPTIDE AND IMMUNE MODULATION | March 2021 | July 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17187264 | IMMUNOCHROMATOGRAPHIC KIT AND METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSIS | February 2021 | April 2023 | Abandon | 26 | 2 | 1 | No | No |
| 17180183 | VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER | February 2021 | February 2024 | Abandon | 36 | 1 | 1 | Yes | No |
| 17261347 | METHODS FOR DUAL DETECTION AND DIFFERENTIATION OF INFECTION BY MYCOBACTERIUM TUBERCULOSIS COMPLEX AND NONTUBERCULOUS MYCOBACTERIA | January 2021 | May 2024 | Abandon | 40 | 2 | 1 | Yes | No |
| 17151445 | Multivalent Streptococcus Vaccines | January 2021 | October 2023 | Abandon | 32 | 6 | 1 | Yes | No |
| 17150025 | FimH mutant, compositions therewith and use thereof | January 2021 | April 2022 | Allow | 15 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DEVI, SARVAMANGALA.
With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DEVI, SARVAMANGALA works in Art Unit 1645 and has examined 1,152 patent applications in our dataset. With an allowance rate of 61.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner DEVI, SARVAMANGALA's allowance rate of 61.7% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DEVI, SARVAMANGALA receive 2.04 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DEVI, SARVAMANGALA is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +50.4% benefit to allowance rate for applications examined by DEVI, SARVAMANGALA. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.6% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.7% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 78.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.2% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.